Literature DB >> 9973695

Mesalazine-induced eosinophilic pneumonia.

K Tanigawa1, K Sugiyama, H Matsuyama, H Nakao, K Kohno, Y Komuro, Y Iwanaga, K Eguchi, M Kitaichi, H Takagi.   

Abstract

A 35-year-old woman with a 6-month history of ulcerative colitis and treatment with oral mesalazine (5-aminosalicylic acid) developed dry cough, low-grade fever and bilaterally wandering pulmonary infiltrates. Improvement in clinical symptoms and radiological abnormalities occurred spontaneously after discontinuation of mesalazine. The transbronchial lung biopsy demonstrated the organizing stage of eosinophilic pneumonia. Drug lymphocyte stimulation test was positive for mesalazine and negative for sulfasalazine and sulfapyridine. The present case indicates that although mesalazine-induced eosinophilic pneumonia is an extremely rare entity, its possibility should be fully considered in patients developing unexplained respiratory symptoms while on mesalazine therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973695     DOI: 10.1159/000029341

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  20 in total

Review 1.  Organising pneumonia.

Authors:  J F Cordier
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

2.  An unusual case of pneumonia.

Authors:  Primiano Iannone; Tiziano Lenzi
Journal:  Intern Emerg Med       Date:  2008-05-15       Impact factor: 3.397

3.  Asymptomatic presentation of mesalamine-induced lung injury in an adolescent with Crohn disease.

Authors:  Rafael Cilloniz; Sarah Elizabeth Chesrown; Regino P Gonzalez-Peralta
Journal:  BMJ Case Rep       Date:  2009-03-20

4.  Mesalazine-induced multi-organ hypersensitivity.

Authors:  Bruno Sposato; Maria Pia Allegri; Maria Piera Riccardi; Silvia Chigiotti; Cesira Nencioni; Barbara Ricciardi; Tiziana Carli; Alberto Cresti; Maria Grazia Perari; Maria Giovanna Migliorini; Mario Toti
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 5.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 6.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

7.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

8.  Mesalazine-induced lung fibrosis.

Authors:  Ebraheem Alskaf; Amer Aljoudeh; Frank Edenborough
Journal:  BMJ Case Rep       Date:  2013-04-09

9.  Respiratory involvement in inflammatory bowel diseases.

Authors:  Nadia D'Andrea; Rossana Vigliarolo; Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2010-06-30

10.  Acute eosinophilic pneumonia related to a mesalazine suppository.

Authors:  Jung Hyun Kim; June-Hyuk Lee; Eun-Suk Koh; Sung Woo Park; An-Soo Jang; Dojin Kim; Choon-Sik Park
Journal:  Asia Pac Allergy       Date:  2013-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.